

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A human or humanized chimeric monoclonal antibody produced in a cell line selected for its properties of particular glycosylation of the Fc fragment of an antibody, or the glycan structure of which has been modified ex vivo, said antibody having an Fc γ RIII (CD16)-type ADCC rate of greater than 60%, 70%, 80% or preferably greater than 90%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, characterized in that it wherein said antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 60%, 100%, or preferably greater than 200%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

2. (Currently Amended) The antibody as claimed in claim 1, characterized in that it wherein said antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and a rate of production of at least one cytokine by a CD16 receptor-expressing effector cell of the immune system of greater than 1000% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

3-21. (Canceled)

22. (New) The antibody as claimed in claim 1, wherein the cytokines that are released are interleukins.

23. (New) The antibody as claimed in claim 1, wherein the cytokines that are released are interferons.

24. (New) The antibody as claimed in claim 1, wherein the cytokines that are released are tissue necrosis factors (TNFs).

25. (New) The antibody as claimed in claim 1, wherein the antibody selected has the ability to induce the secretion of at least one cytokine chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF α , TGF β , IP10 and IFN γ , by the CD16 receptor-expressing effector cells.

26. (New) The antibody as claimed in claim 1, wherein the antibody selected has the ability to induce the secretion of IL-2 by CD16 receptor-expressing effector cells of the immune system.

27. (New) The antibody as claimed in claim 1, wherein the effector cell is a CD16 receptor-expressing Jurkat cell or by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group.

28. (New) The antibody as claimed in claim 1, wherein said antibody is produced in a cell line of the rat myeloma type, in particular YB2/0.

29. (New) The antibody as claimed in claim 1, wherein said antibody is directed against an antigen of a pathological cell or of an organism that is pathogenic for humans, in particular against an antigen of a cancer cell.

30. (New) The antibody as claimed in claim 29, wherein said antibody's specificity is to anti-Rhesus D of human red blood cells.

31. (New) The antibody as claimed in claim 30, wherein said antibody is an anti-HLA-DR.

32. (New) The antibody as claimed in claim 31, wherein said antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a concentration of 10 ng/ml or less, compared with the same antibody expressed in the CHO line, the expression line for apolizumab.

33. (New) The antibody as claimed in claim 31, wherein said antibody is produced in a rat myeloma line, in particular YB2/0.

34. (New) The antibody as claimed in claim 29, wherein said antibody is an anti-CD20.

35. (New) The antibody as claimed in claim 34, wherein said antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a concentration of 10 ng/ml or less, compared with rituximab.

36. (New) The antibody as claimed in claim 34, wherein said antibody is produced in a rat myeloma line, in particular YB2/0.

37. (New) The antibody as claimed in claim 29, wherein said antibody is selected from anti-Ep-CAM, anti-KIR3DL2, anti-VEGFR, anti-HER1, anti-HER2, anti-GD, anti-GD2, anti-GD3, anti-CD23, anti-CD30, anti-CD33, anti-CD38, anti-CD44, anti-CD52, anti-CA125 and anti-ProteinC; anti-Ep-CAM, anti-HER2, anti-CD52, anti-HER1, anti-GD3, anti-CA125 anti-GD, anti-GD2, anti-CD23 and anti-ProteinC; antivirals: HBV, HCV, HIV and RSV, anti-idiotypes specific for inhibitors, for example for clotting factors including FVIII and FIX.

38. (New) The antibody as claimed in claim 1, wherein said antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 100%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

39. (New) The antibody as claimed in claim 1, wherein said antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 200%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

40. (New) The antibody as claimed in claim 1, wherein said antibody has an Fc γ RIII (CD16)-type ADCC rate of greater than 70%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

41. (New) The antibody as claimed in claim 1, wherein said antibody has an Fc γ RIII (CD16)-type ADCC rate of greater than 80%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

42. (New) The antibody as claimed in claim 1, wherein said antibody has an Fc γ RIII (CD16)-type ADCC rate of greater than 90%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.